研究生导师-天津市肿瘤医院-北方网企业建站

国家自然科学基金面上项目（2018/01-2021/12）：TGFβ反式激活EGFR信号通路并促进乳腺癌细胞侵袭转移的分子机制研究（81772804，55万元）
国家自然科学基金面上项目（2014/01-2017/12）：Anxa2介导IL-6诱导的SHP2/Erk和JAK2/STAT3信号通路激活并促进乳腺癌细胞上皮间质转化的分子机制研究（81372844，72万元）
教育部高等学校博士学科点专项科研基金（2014/01-2016/12）：Anxa2介导IL-6信号通路并促进乳腺癌细胞上皮间质转化的分子机制研究（20131202110002，12万元）
863计划子课题（2012/01-2015/12）：肿瘤蛋白质分子标志物的研究与开发（2012AA020206，65万元）
天津市自然科学基金重点项目（2012/04-2015/03）：Anxa2调控STAT3活性和乳腺癌细胞侵袭的作用机制研究（12JCZDJC24500，20万元）
国家自然科学基金面上项目（2011/01-2013/12）：MDR1与Anxa2相互作用调节耐药乳腺癌细胞侵袭的分子机制研究（81071731，31万元）
863计划（2008/01-2010/12）：双亲性复合靶向控释纳米药物制剂（2007AA021802，408万）

　　近年发表SCI论文(*通讯作者)：

1. Zhao Y, Ma J, Fan Y, Wang Z, Tian R, Ji W, Zhang F*, Niu R*: TGF-beta transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways. Molecular oncology 2018, 12(3):305-321.

2. Yuan J, Yang Y, Gao Z, Wang Z, Ji W, Song W, Zhang F*, Niu R*: Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells. Breast Cancer Res Treat2017, 164(2):327-340.

3. Sun X, Zhang J, Wang Z, Ji W, Tian R, Zhang F*, Niu R*: Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells. International journal of molecular sciences 2017, 18(2).

4. Yang Y, Wu N, Wang Z, Zhang F, Tian R, Ji W, Ren X, Niu R*: Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells. International journal of molecular sciences 2016, 17(10).

5. Zhang J, Zhang F, Niu R*: Functions of Shp2 in cancer. J Cell Mol Med 2015, 19(9):2075-2083.

6. Zhang F, Wang Z, Yuan J, Wei X, Tian R, Niu R*: RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway. Breast Cancer Res Treat 2015, 153(2):263-275.

7. Zhang F, Wang Z, Fan Y, Xu Q, Ji W, Tian R, Niu R*: Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells. International journal of molecular sciences 2015, 16(10):24772-24790.

8. Zhang F, Liu Y, Wang Z, Sun X, Yuan J, Wang T, Tian R, Ji W, Yu M, ZhaoY,Niu R*: A novel Anxa2-interacting protein Ebp1 inhibits cancer proliferation and invasion by suppressing Anxa2 protein level. Mol Cell Endocrinol 2015, 411:75-85.

9. Zhang F, Zhang H, Wang Z, Yu M, Tian R, Ji W, Yang Y, Niu R*: P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells. Biochem Pharmacol 2014, 87(2):292-302.

10. Wu B, Zhang F, Yu M, Zhao P, Ji W, Zhang H, Han J, Niu R*: Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells. Cell proliferation 2012, 45(3):189-198.

11. Wang H, Wang S, Liao Z, Zhao P, Su W, Niu R*, Chang J: Folate-targeting magnetic core-shell nanocarriers for selective drug release and imaging. International journal of pharmaceutics 2012, 430(1-2):342-349.

12. Han J, Zhang F, Yu M, Zhao P, Ji W, Zhang H, Wu B, Wang Y, Niu R*: RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Lett 2012, 321(1):80-88.

　　博士生导师：李祥春

　　天津医科大学肿瘤医院肿瘤研究所

　　公共实验室

　　研究员，教授，博士生导师

　　2016年毕业于香港中文大学，生物信息学方向，长期从事肿瘤基因组二代测序数据分析和挖掘工作的研究，对肿瘤基因组学前沿研究方法和思路有深刻理解。熟练掌握肿瘤基因分析技术方法：数据比对、突变检测、结构变异分析、肿瘤异质性分析、突变特征图谱分析、驱动基因筛选、分子分型和标记物筛选和新抗原分析等。近5年来在国际权威刊物（Nature、Gut、PNAS、Nature Communications、Cancer Research和Molecular Biology and Evolution等）上以第一作者身份共发表SCI论文8篇，截止到目前为止一共发表近20篇SCI论文。　

近5年发表SCI论文：

1. Xiangchun Li, MY Wang, Meng Yang, Hongji Dai, Baifeng Zhang, Wei Wang, Xinlei Chu, Xin Wang, Hong Zheng, RuifangNiu, Kexin Chen. A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Annals of Oncology. 2018 Jan 16. (IF: 11.855)

2. William K.K. Wu, Xiangchun Li, Xiansong Wang, Rudin Z.W. Dai, Alfred S.L. Cheng, Maggie H.T. Wang, Thomas Kwong, Tai C. Chow, Jun Yu, Matthew T.V. Chan, S. H. W. Oncogenes without a neighboring tumor-suppressor gene are more prone to amplification. MolBiolEvol. (2017). doi:10.1093 (IF: 13)

3. Li, Xiangchun, Wu, W. K. K., Xing, R., Wong, S. H., & Liu, Y. (2016). Distinct subtypes of gastric cancer defined by molecular characterization include novel mutational signatures with prognostic capability, Cancer Research, 76(7), 1724–1733. doi:10.1158/0008-5472.CAN-15-2443 (IF: 9.329)

4. Nakatsu, G., Li, Xiangchun, Zhou, H., Sheng, J., Wong, S. H., Wu, W. K. K., ... Sung, J. J. Y. (2015). Gut mucosal microbiome across stages of colorectal carcinogenesis. Nature Communications, 6, 8727. doi:10.1038/ncomms9727 (IF: 11.47)

5. Chen, K., Yang, D., Li, Xiangchun, Sun, B., Song, F., Cao, W., ... Gao, Z. (2015). Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy. Proceedings of the National Academy of Sciences, 6(1), 1–6. doi:10.1073/pnas.1422640112 (IF: 9.674)

6. Song, Y., Li, L., Ou, Y., Gao, Z., Li, E., Li,Xiangchun, ... Zhan, Q. (2014). Identification of genomic alterations in oesophageal squamous cell cancer. Nature, 509(7498), 91–5. doi:10.1038/nature13176 (IF: 41.456)

7. Yu, J., Wu, W. K. K., Li, Xiangchun, X. X., He, J., Li, X.-X. X., Ng, S. S. M., ... Sung, J. J. Y. (2015). Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut, 64(4), 636–45. doi:10.1136/gutjnl- 2013-306620 (IF: 14.66)

8. Song, F., Li,Xiangchun, Song, F., Zhao, Y., & Li, H. (2015). Comparative genomic analysis reveals bilateral breast cancers are genetically independent. Oncotarget. doi:10.18632/oncotarget.5569 (IF: 6.359)

9. Li, C., Gao, Z., Li, F., Li, Xiangchun, Sun, Y., Wang, M. M., ... Wei, Q. (2015). Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. Scientific Reports, 5(August), 14237. doi:10.1038/srep14237 (IF: 5.578)

10. Cao, Y., He, M., Gao, Z., Peng, Y., ...Li, Xiangchun, ... Ning, G. (2014). Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome. Science, 344(6186), 913–7. doi:10.1126/science.1249480 (IF: 33.611)

11.Zhang, L., Zhou, Y., Cheng, C., Cui, H., Cheng, ...Li, Xiangchun, ... Cui, Y. (2015). Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. American Journal of Human Genetics, 96(4), 597–611. doi:10.1016/j.ajhg.2015.02.017 (IF: 10.931)

12.Yu, C., Yu, J., Yao, X., Wu, W. K. K., Lu, Y., ... Li,Xiangchun, ... Wang, J. J. (2014). Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. Cell Research, 24(6), 701–12. doi:10.1038/cr.2014.43 (IF: 12.413)

13.Zhao, Y., Yang, J., Chen, Z., Gao, Z., Zhou, F., Li, Xiangchun, ... He, J. (2014). Identification of somatic alterations in stage I lung adenocarcinomas by next- generation sequencing. Genes Chromosomes and Cancer, 53(4), 289–298. doi:10.1002/gcc.22138 (IF: 4.041)

14.Xu, L., Li, X. X., Cai, M., Chen, J., Li, X. X., Wu, W. K. K., ...Li, Xiangchun, ... Yu, J. (2015). Increased expression of Solute carrier family 12 member 5 via gene amplification contributes to tumour progression and metastasis and associates with poor survival in colorectal cancer. Gut, 1–12. doi:10.1136/gutjnl-2014-308257 (IF: 14.66)

15.Liu, L., Xu, Y., He, M., Zhang, M., Cui, F., Lu, L., ...Li, Xiangchun, ... Esteban, M. A. (2014). Transcriptional pause release is a rate-limiting step for somatic cell reprogramming. Cell Stem Cell, 15(5), 574–588. doi:10.1016/j.stem.2014.09.018 (IF: 22.268)

16.Cheng, C., Zhou, Y., Li, H., Xiong, T., Li, S., Bi, Y., ... Li, Xiangchun, ... Cui, Y. (2016). Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma. The American Journal of Human Genetics, 1–19. doi:10.1016/j.ajhg.2015.12.013 (IF: 10.931)

17.Tsang, D. P. F., Wu, W. K. K., Kang, W., Lee, Y.-Y., Wu, F., Yu, Z., ... Li, Xiangchun, ... Cheng, A. S. L. (2016). Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates Nuclear Factor-κB in hepatocellular carcinoma. The Journal of Pathology. doi:10.1002/path.4688 (IF: 7.429)

18.Tang, S., Wu, W. K. K., Li, Xiangchun, Wong, S. H., Wong, N., Chan, M. T. V., ... Yu, J. (2016). Stratification of Digestive Cancers with Different Pathological Features and Survival Outcomes by MicroRNA Expression. Scientific Reports, 6(4), 24466. doi:10.1038/srep24466 (IF: 5.578)

　　硕士生导师：张飞

　　天津医科大学肿瘤医院肿瘤研究所

　　公共实验室

　　副研究员、硕士研究生导师

　　2004年毕业于新乡医学院临床医学专业，2007年获得天津医科大学生物化学与分子生物学硕士学位，2013年获得天津医科大学肿瘤学博士学位。2008-2009曾在香港科技大学生物化学系进修。2015年获“天津市创新人才推进计划-青年科技优秀人才”称号，2015年获得天津市优秀博士论文，2016年获得第9届中国肿瘤学术大会优秀论文一等奖，2017年入选天津市“131”创新型人才第二层次，并获得天津医科大学肿瘤医院首批“青年创新人才”称号；发表SCI收录论文15篇，主持国家自然科学基金项目2项，天津市科委课题2项，天津市教委课题1项。

　　研究方向：

基于蛋白质组学和高通量测序等研究方法筛选和鉴定与肿瘤发生发展密切相关的蛋白质，并解析相应的信号传导网络。
聚焦肿瘤多药耐药的机制研究，探索导致耐药肿瘤侵袭转移能力增强的分子机制，为临床耐药肿瘤的治疗提供新思路。
研究癌细胞侵袭转移的分子机制，解析调控癌细胞侵袭转移的关键信号通路，为临床转移肿瘤的治疗提供新靶点。

　　近年来主持的研究项目：

国家自然科学基金面上项目（2015/01-2018/12）：P-glycoprotein与Rack1和Src相互作用并促进耐药乳腺癌细胞侵袭转移的分子机制研究（81472474，85万元）
天津市自然科学基金（2016/04-2019/03）：Her3表达上调促进耐药乳腺癌细胞侵袭的作用机制研究（16JCYBJC25400，10万元）
天津市自然科学基金（2012/04-2015/03）：mTORC2调节TGFbeta诱导肺癌细胞发生EMT的分子机制研究，编号：（12JCQNJC07000，8万元）
国家自然科学基金面上项目（2011/01-2013/12）：p32在调控PKCzeta活性和乳腺癌细胞趋化运动的作用机制研究（81001188，20万元）
天津医科大学肿瘤医院青年创新优秀人才基金（2016/10-2021/10）：多药耐药促进肿瘤转移的分子机制（30万元）

近年来发表SCI论文(*通讯作者)：

1. Zhao Y, Ma J, Fan Y, Wang Z, Tian R, Ji W, Zhang F*, Niu R*: TGF-beta transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways. Molecular oncology 2018, 12(3):305-321.

2. Yuan J, Yang Y, Gao Z, Wang Z, Ji W, Song W, Zhang F*, Niu R*: Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells. Breast Cancer Res Treat 2017, 164(2):327-340.

3. Sun X, Zhang J, Wang Z, Ji W, Tian R, Zhang F*, Niu R*: Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells. International journal of molecular sciences 2017, 18(2).

4. Zhang F, Wang Z, Yuan J, Wei X, Tian R, Niu R*: RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway. Breast Cancer Res Treat 2015, 153(2):263-275.

5. Zhang F, Wang Z, Fan Y, Xu Q, Ji W, Tian R, Niu R*: Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells. International journal of molecular sciences 2015, 16(10):24772-24790.

6. Zhang F, Liu Y, Wang Z, Sun X, Yuan J, Wang T, Tian R, Ji W, Yu M, Zhao Y,Niu R*:A novel Anxa2-interacting protein Ebp1 inhibits cancer proliferation and invasion by suppressing Anxa2 protein level. Mol Cell Endocrinol 2015, 411:75-85.

7. Zhang F, Zhang H, Wang Z, Yu M, Tian R, Ji W, Yang Y, Niu R*: P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells. Biochem Pharmacol 2014, 87(2):292-302.

8. Han J, Zhang F, Yu M, Zhao P, Ji W, Zhang H, Wu B, Wang Y, Niu R: RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Lett 2012, 321(1):80-88.

9. Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, Cao W, Wei X, Cao X, Hao X et al: mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. Cancer Res 2010, 70(22):9360-9370.

10. Zhang F, Zhang L, Zhang B, Wei X, Yang Y, Qi RZ, Ying G, Zhang N, Niu R: Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 2009, 8(11):5041-5047.

法律声明 | 联系我们